ALTITUDE Diabetes Study CSPP100E2337
ALTITUDE Diabetes Study CSPP100E2337
Novartis Clinical Trials
The purpose of this clinical research study is to determine if the investigational drug aliskiren delays or prevents the occurrence of heart and/or kidney complications in participants with type 2 diabetes who are taking medications for heart and/or kidney problems. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Depending on when participants join this study, their participation may last for two to four years with up to 23 scheduled visits.
Protocol Number: CSPP100E2337
